TransCode Therapeutics (NASDAQ:RNAZ) Trading Down 8.1% – Should You Sell?

TransCode Therapeutics, Inc. (NASDAQ:RNAZ) shares dropped 8.1% during mid-day trading on Wednesday . The stock traded as low as $0.66 and last traded at $0.68. Approximately 1,056,975 shares traded hands during mid-day trading, a decline of 20% from the average daily volume of 1,324,074 shares. The stock had previously closed at $0.74.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “buy” rating and set a $3.00 price objective on shares of TransCode Therapeutics in a research report on Friday, September 6th.

TransCode Therapeutics Trading Up 2.5 %

The stock’s 50-day moving average is $0.40 and its two-hundred day moving average is $0.70.

TransCode Therapeutics (NASDAQ:RNAZ) last issued its quarterly earnings results on Wednesday, August 14th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.58) by ($0.16). As a group, analysts expect that TransCode Therapeutics, Inc. will post -2.06 earnings per share for the current fiscal year.

Institutional Investors Weigh In On TransCode Therapeutics

A hedge fund recently bought a new stake in TransCode Therapeutics stock. Virtu Financial LLC acquired a new stake in TransCode Therapeutics, Inc. (NASDAQ:RNAZ) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 55,329 shares of the company’s stock, valued at approximately $37,000. Virtu Financial LLC owned about 0.84% of TransCode Therapeutics as of its most recent filing with the Securities and Exchange Commission.

About TransCode Therapeutics

TransCode Therapeutics, Inc, a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others.